How The Parts Add Up: VONE Targets $274
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 22 2024
0mins
Source: NASDAQ.COM
Vanguard Russell 1000 ETF Analysis: The Vanguard Russell 1000 ETF (VONE) has an implied analyst target price of $274.39, indicating a potential upside of 10.34% from its current trading price of $248.67.
Notable Holdings with Upside Potential: Key holdings within VONE, such as Apellis Pharmaceuticals (APLS), Peloton Interactive (PTON), and Intra-Cellular Therapies (ITCI), show significant upside potential based on analysts' target prices, suggesting optimism about their future performance.
Analyst Views on APLS
Wall Street analysts forecast APLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLS is 43.25 USD with a low forecast of 22.00 USD and a high forecast of 117.80 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 20.950
Low
22.00
Averages
43.25
High
117.80
Current: 20.950
Low
22.00
Averages
43.25
High
117.80
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
